Ladenburg lowered the firm’s price target on Bionano Genomics to $6.80 from $11 and keeps a Buy rating on the shares post the Q1 report. The analyst believes Bionano is positioned well for continued sales growth driven by systems and flowcells.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics announces upgrades to cancer analysis suite
- Options Volatility and Implied Earnings Moves Today, May 08, 2024
- Options Volatility and Implied Earnings Moves This Week, May 06 – May 10, 2024
- Bionano Genomics announces publication on OGM’s structural variation detection
- Bionano Genomics enters partnership with Diagens